Electra Therapeutics director holds 77,714 options
A newly filed Form 3 shows director Matthew K. Fust’s existing Electra Therapeutics stock option grants, including strike prices, share amounts and long-dated vesting schedules.
Rhea-AI Filing Summary
Electra Therapeutics, Inc. (ETRA) reported that director Matthew K. Fust holds three director stock options covering its common stock. These options allow the purchase of 59,086 shares at $4.40 per share expiring November 16, 2033, 77,714 shares at $4.96 per share expiring February 12, 2036, and 22,632 shares at $15.00 per share expiring September 16, 2036.
One grant vests over four years starting October 16, 2023 with monthly vesting thereafter and is early exercisable subject to the company’s right of repurchase; another vests monthly from February 1, 2026 on the same early-exercise and repurchase terms; the third vests on the earlier of September 17, 2027 or the next annual stockholder meeting.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Fust Matthew K
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Director Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Director Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Director Stock Option (right to buy) F3 | -- | -- | -- |
Holdings After Transaction:
Director Stock Option (right to buy) — 159,432 contracts (Direct)
Footnotes (3)
- F1. 1/4th of the total shares subject to this option vested one year after October 16, 2023, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
- F2. 1/48th of the total shares subject to this option shall vest monthly commencing from February 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
- F3. The shares subject to this option shall vest on the earlier of September 17, 2027 and the date of the next annual meeting of the Issuer's stockholders.
Key Figures
Option 1 underlying shares: 59,086 shares
Option 1 exercise price: $4.40 per share
Option 2 underlying shares: 77,714 shares
+5 more
8 metrics
Option 1 underlying shares
59,086 shares
Director stock option with $4.40 exercise price expiring November 16, 2033
Option 1 exercise price
$4.40 per share
Director stock option over common stock expiring November 16, 2033
Option 2 underlying shares
77,714 shares
Director stock option with $4.96 exercise price expiring February 12, 2036
Option 2 exercise price
$4.96 per share
Director stock option over common stock expiring February 12, 2036
Option 3 underlying shares
22,632 shares
Director stock option with $15.00 exercise price expiring September 16, 2036
Option 3 exercise price
$15.00 per share
Director stock option over common stock expiring September 16, 2036
Monthly vesting fraction (F1)
1/48 of total shares
Portion of the October 16, 2023 option vesting each month after the first year
Monthly vesting fraction (F2)
1/48 of total shares
Portion of the February 1, 2026 option vesting each month
Key Terms
early exercisable, right of repurchase, vest monthly, annual meeting of the Issuer's stockholders
4 terms
early exercisable financial
"The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase."
right of repurchase financial
"The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase."
vest monthly financial
"1/48th of the total shares subject to this option shall vest monthly commencing from February 1, 2026."
annual meeting of the Issuer's stockholders financial
"The shares subject to this option shall vest on the earlier of September 17, 2027 and the date of the next annual meeting of the Issuer's stockholders."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider holdings does director Matthew K. Fust report in Electra Therapeutics (ETRA)?
Matthew K. Fust reports three director stock options over Electra Therapeutics common stock, covering 59,086 shares at $4.40, 77,714 shares at $4.96, and 22,632 shares at $15.00, each with long-dated expiration and specified vesting schedules.
What are the strike prices and expirations of the reported ETRA director stock options?
The options reported by Matthew K. Fust have strike prices of $4.40 expiring November 16, 2033, $4.96 expiring February 12, 2036, and $15.00 expiring September 16, 2036, each for Electra Therapeutics common stock.
How do the Electra Therapeutics (ETRA) options granted in October 2023 vest?
For the grant tied to October 16, 2023, one-fourth of the shares vested one year after that date and the remaining three-fourths vest in equal monthly installments over the following three years. The shares are early exercisable, subject to Electra’s right of repurchase.
What is the vesting schedule for Matthew K. Fust’s February 2026 Electra Therapeutics option grant?
The option with a $4.96 exercise price vests in equal monthly installments starting February 1, 2026. These shares are described as early exercisable, and any early-exercised shares are subject to Electra Therapeutics’ contractual right of repurchase.
When will the third Electra Therapeutics (ETRA) director option held by Matthew K. Fust vest?
The third option, with a $15.00 exercise price, will vest on the earlier of September 17, 2027 or the date of the next annual meeting of Electra Therapeutics’ stockholders, as disclosed in the vesting terms.
Does this Form 3 for Electra Therapeutics (ETRA) report any stock purchases or sales?
No. The Form 3 reports existing stock option holdings for director Matthew K. Fust and their vesting terms. It does not report any open-market purchases or sales of Electra Therapeutics common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
